The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy.
Peroral endoscopy was performed in 56 patients with rheumatic disease who had been taking 8 or more aspirin tablets daily for more than 3 months yet who had no major gastrointestinal symptoms or history of peptic ulcer disease. Duodenal mucosal lesions were observed in 16 patients; 15 (27%) had erythema, 7 (13%) had erosions, and 2 (4%) had ulcers. The prevalence of duodenal lesions was the same in patients taking regular, buffered, or enteric-coated aspirin preparations. Patients with duodenal lesions were more likely to have associated gastric lesions.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000009:adverse effects* / Q000627:therapeutic use; D002021:Buffers; D004378:Duodenal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D004381:Duodenal Ulcer / Q000139:chemically induced; D004724:Endoscopy; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000139:chemically induced / Q000453:epidemiology; D013608:Tablets, Enteric-Coated
D002021:Buffers; D013608:Tablets, Enteric-Coated; D001241:Aspirin